Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the southwest oncology group

David R Gandara, John Crowley, Robert B. Livingston, Edith A. Perez, Charles W. Taylor, Geoffrey Weiss, John R. Neefe, Laura F. Hutchins, Ralph W. Roach, Steven M. Grunberg, Thomas J. Braun, Ronald B. Natale, Stanley P. Balcerzak

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Purpose: To test the concept that cisplatin dose-intensity is important in the treatment of non-small-cell lung cancer (NSCLC), the Southwest Oncology Group (SWOG) performed a randomized trial comparing standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles, high-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles, and high-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1. To isolate the effects of dose-intensity versus total dose, the planned cumulative cisplatin dose was 800 mg/m2 in each arm. Patients and Methods: Between July 1988 and April 1990, 356 patients were enrolled and 323 were eligible and assessable. All patients had metastatic, measurable disease, were chemotherapy-naive, and had a performance status (PS) of 0 to 2. Results: Confirmed complete plus partial response rates were SDCP, 12%; HDCP, 14%; and HDCP-M, 27% (P < .05). Complete responses were uncommon (HDCP, 3%; HDCP-M, 4%) and were observed only in the high-dose arms. Progressive disease occurred more frequently in the SDCP arm (57%) compared with HDCP (38%) or HDCP-M (34%) (P < .05). However, there were no significant differences in median survival times (SDCP, 6.9 months; HDCP, 5.3 months; HDCP-M, 7.2 months; P = .53). The mean delivered dose-intensity for cisplatin was significantly greater in the high-dose arms: HDCP 41 mg/m2/wk and HDCP-M 39 mg/m2/wk, versus SDCP 23 mg/m2/wk (P = .05). The high-dose arms resulted in an increased incidence of ototoxicity, emesis, and myelosuppression, but similar degrees of renal toxicity and neuropathy compared with SDCP. Conclusion: This study does not confirm evidence of a steep clinical dose-response curve for cisplatin in NSCLC at the cisplatin dose-intensities achieved. The addition of mitomycin increases the response rate, but does not improve survival. Continued evaluation of new agents in this disease is warranted.

Original languageEnglish (US)
Pages (from-to)873-878
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number5
StatePublished - 1993

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Mitomycin
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gandara, D. R., Crowley, J., Livingston, R. B., Perez, E. A., Taylor, C. W., Weiss, G., ... Balcerzak, S. P. (1993). Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the southwest oncology group. Journal of Clinical Oncology, 11(5), 873-878.

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer : A phase III study of the southwest oncology group. / Gandara, David R; Crowley, John; Livingston, Robert B.; Perez, Edith A.; Taylor, Charles W.; Weiss, Geoffrey; Neefe, John R.; Hutchins, Laura F.; Roach, Ralph W.; Grunberg, Steven M.; Braun, Thomas J.; Natale, Ronald B.; Balcerzak, Stanley P.

In: Journal of Clinical Oncology, Vol. 11, No. 5, 1993, p. 873-878.

Research output: Contribution to journalArticle

Gandara, DR, Crowley, J, Livingston, RB, Perez, EA, Taylor, CW, Weiss, G, Neefe, JR, Hutchins, LF, Roach, RW, Grunberg, SM, Braun, TJ, Natale, RB & Balcerzak, SP 1993, 'Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the southwest oncology group', Journal of Clinical Oncology, vol. 11, no. 5, pp. 873-878.
Gandara, David R ; Crowley, John ; Livingston, Robert B. ; Perez, Edith A. ; Taylor, Charles W. ; Weiss, Geoffrey ; Neefe, John R. ; Hutchins, Laura F. ; Roach, Ralph W. ; Grunberg, Steven M. ; Braun, Thomas J. ; Natale, Ronald B. ; Balcerzak, Stanley P. / Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer : A phase III study of the southwest oncology group. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 5. pp. 873-878.
@article{99352a5cc8be43d082b4c80983fdb81e,
title = "Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the southwest oncology group",
abstract = "Purpose: To test the concept that cisplatin dose-intensity is important in the treatment of non-small-cell lung cancer (NSCLC), the Southwest Oncology Group (SWOG) performed a randomized trial comparing standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles, high-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles, and high-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1. To isolate the effects of dose-intensity versus total dose, the planned cumulative cisplatin dose was 800 mg/m2 in each arm. Patients and Methods: Between July 1988 and April 1990, 356 patients were enrolled and 323 were eligible and assessable. All patients had metastatic, measurable disease, were chemotherapy-naive, and had a performance status (PS) of 0 to 2. Results: Confirmed complete plus partial response rates were SDCP, 12{\%}; HDCP, 14{\%}; and HDCP-M, 27{\%} (P < .05). Complete responses were uncommon (HDCP, 3{\%}; HDCP-M, 4{\%}) and were observed only in the high-dose arms. Progressive disease occurred more frequently in the SDCP arm (57{\%}) compared with HDCP (38{\%}) or HDCP-M (34{\%}) (P < .05). However, there were no significant differences in median survival times (SDCP, 6.9 months; HDCP, 5.3 months; HDCP-M, 7.2 months; P = .53). The mean delivered dose-intensity for cisplatin was significantly greater in the high-dose arms: HDCP 41 mg/m2/wk and HDCP-M 39 mg/m2/wk, versus SDCP 23 mg/m2/wk (P = .05). The high-dose arms resulted in an increased incidence of ototoxicity, emesis, and myelosuppression, but similar degrees of renal toxicity and neuropathy compared with SDCP. Conclusion: This study does not confirm evidence of a steep clinical dose-response curve for cisplatin in NSCLC at the cisplatin dose-intensities achieved. The addition of mitomycin increases the response rate, but does not improve survival. Continued evaluation of new agents in this disease is warranted.",
author = "Gandara, {David R} and John Crowley and Livingston, {Robert B.} and Perez, {Edith A.} and Taylor, {Charles W.} and Geoffrey Weiss and Neefe, {John R.} and Hutchins, {Laura F.} and Roach, {Ralph W.} and Grunberg, {Steven M.} and Braun, {Thomas J.} and Natale, {Ronald B.} and Balcerzak, {Stanley P.}",
year = "1993",
language = "English (US)",
volume = "11",
pages = "873--878",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer

T2 - A phase III study of the southwest oncology group

AU - Gandara, David R

AU - Crowley, John

AU - Livingston, Robert B.

AU - Perez, Edith A.

AU - Taylor, Charles W.

AU - Weiss, Geoffrey

AU - Neefe, John R.

AU - Hutchins, Laura F.

AU - Roach, Ralph W.

AU - Grunberg, Steven M.

AU - Braun, Thomas J.

AU - Natale, Ronald B.

AU - Balcerzak, Stanley P.

PY - 1993

Y1 - 1993

N2 - Purpose: To test the concept that cisplatin dose-intensity is important in the treatment of non-small-cell lung cancer (NSCLC), the Southwest Oncology Group (SWOG) performed a randomized trial comparing standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles, high-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles, and high-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1. To isolate the effects of dose-intensity versus total dose, the planned cumulative cisplatin dose was 800 mg/m2 in each arm. Patients and Methods: Between July 1988 and April 1990, 356 patients were enrolled and 323 were eligible and assessable. All patients had metastatic, measurable disease, were chemotherapy-naive, and had a performance status (PS) of 0 to 2. Results: Confirmed complete plus partial response rates were SDCP, 12%; HDCP, 14%; and HDCP-M, 27% (P < .05). Complete responses were uncommon (HDCP, 3%; HDCP-M, 4%) and were observed only in the high-dose arms. Progressive disease occurred more frequently in the SDCP arm (57%) compared with HDCP (38%) or HDCP-M (34%) (P < .05). However, there were no significant differences in median survival times (SDCP, 6.9 months; HDCP, 5.3 months; HDCP-M, 7.2 months; P = .53). The mean delivered dose-intensity for cisplatin was significantly greater in the high-dose arms: HDCP 41 mg/m2/wk and HDCP-M 39 mg/m2/wk, versus SDCP 23 mg/m2/wk (P = .05). The high-dose arms resulted in an increased incidence of ototoxicity, emesis, and myelosuppression, but similar degrees of renal toxicity and neuropathy compared with SDCP. Conclusion: This study does not confirm evidence of a steep clinical dose-response curve for cisplatin in NSCLC at the cisplatin dose-intensities achieved. The addition of mitomycin increases the response rate, but does not improve survival. Continued evaluation of new agents in this disease is warranted.

AB - Purpose: To test the concept that cisplatin dose-intensity is important in the treatment of non-small-cell lung cancer (NSCLC), the Southwest Oncology Group (SWOG) performed a randomized trial comparing standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles, high-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles, and high-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1. To isolate the effects of dose-intensity versus total dose, the planned cumulative cisplatin dose was 800 mg/m2 in each arm. Patients and Methods: Between July 1988 and April 1990, 356 patients were enrolled and 323 were eligible and assessable. All patients had metastatic, measurable disease, were chemotherapy-naive, and had a performance status (PS) of 0 to 2. Results: Confirmed complete plus partial response rates were SDCP, 12%; HDCP, 14%; and HDCP-M, 27% (P < .05). Complete responses were uncommon (HDCP, 3%; HDCP-M, 4%) and were observed only in the high-dose arms. Progressive disease occurred more frequently in the SDCP arm (57%) compared with HDCP (38%) or HDCP-M (34%) (P < .05). However, there were no significant differences in median survival times (SDCP, 6.9 months; HDCP, 5.3 months; HDCP-M, 7.2 months; P = .53). The mean delivered dose-intensity for cisplatin was significantly greater in the high-dose arms: HDCP 41 mg/m2/wk and HDCP-M 39 mg/m2/wk, versus SDCP 23 mg/m2/wk (P = .05). The high-dose arms resulted in an increased incidence of ototoxicity, emesis, and myelosuppression, but similar degrees of renal toxicity and neuropathy compared with SDCP. Conclusion: This study does not confirm evidence of a steep clinical dose-response curve for cisplatin in NSCLC at the cisplatin dose-intensities achieved. The addition of mitomycin increases the response rate, but does not improve survival. Continued evaluation of new agents in this disease is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0027295214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027295214&partnerID=8YFLogxK

M3 - Article

C2 - 8387576

AN - SCOPUS:0027295214

VL - 11

SP - 873

EP - 878

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -